The complexity of turning a new drug into a successful asset remains a hurdle even beyond the coveted FDA approval.
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
included in this trendline:
- Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
- Hemophilia gene therapies are struggling on the market, even as innovation soars
- As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Offered Free by: PharmaVoice’s and EVERSANA
See All Resources from: PharmaVoice’s and EVERSANA
